Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations

Pain

Volumn 154, Issue 7, 2013, Pages 997-1008

  Smith, Shannon M ^a   Wang, Anthony T ^b   Katz, Nathaniel P ^c,d   McDermott, Michael P ^a   Burke, Laurie B ^e   Coplan, Paul ^f,g   Gilron, Ian ^h   Hertz, Sharon H ^e   Lin, Allison H ^e   Rappaport, Bob A ^e   Rowbotham, Michael C ⁱ   Sampaio, Cristina ^j   Sweeney, Michael ^k   Turk, Dennis C ^l   Dworkin, Robert H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Analgesic Solutions   (United States)

^d TUFTS UNIVERSITY   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f PURDUE PHARMA L P   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^j CHDI   (United States)

^k Depomed   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Adverse events; Analgesic medications; Clinical trials; CONSORT; Systematic review

Indexed keywords

ANALGESIC AGENT;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; HUMAN; LABORATORY TEST; METHODOLOGY; PAIN; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; VITAL SIGN;

EID: 84878785567     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.03.003     Document Type: Article

References (46)

1. D.G. Altman, and J.M. Bland Absence of evidence is not evidence of absence BMJ 311 1995 48
2. M. Amanzio, L.L. Corazzini, L. Vase, and F. Benedetti A systematic review of adverse events in placebo groups of anti-migraine clinical trials PAIN® 146 2009 261 269
3. R.B. Anderson, N.K. Hollenberg, and G.H. Williams Physical symptoms distress index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life Arch Intern Med 159 1999 693 700
4. E. Basch The missing voice of patients in drug-safety reporting N Engl J Med 362 2010 865 869
5. S. Bent, A. Padula, and A.L. Avins Brief communication: better ways to question patients about adverse events Ann Intern Med 144 2006 257 261
6. H. Bibawy, A. Cossu, S. Cogan, and R. Rosenfeld Reporting of harms and adverse events in otolaryngology journals Otolaryngol Head Neck Surg 140 2009 241 244
7. M.Y. Chowers, B.S. Gottesman, L. Leibovici, U. Pielmeier, S. Andreassen, and M. Paul Reporting of adverse events in randomized controlled trials of highly antiretroviral therapy: systematic review J Antimicrob Chemother 64 2009 239 250
8. V.R. Cornelius, O. Sauzet, J.E. Williams, S. Ayis, P. Farquhar-Smith, J.R. Ross, R.A. Branford, and J.L. Peacock Adverse event reporting in randomised controlled trials of neuropathic pain: considerations for future practice PAIN® 154 2013 213 220
9. T.W. de Vries, and E.N. van Roon Low quality of reporting adverse drug reactions in paediatric randomised controlled trials Arch Dis Child 95 2010 1023 1026
10. R.H. Dworkin, D.C. Turk, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, N.P. Katz, R.D. Kerns, G. Stucki, R.R. Allen, N. Bellamy, D.B. Carr, J. Chandler, P. Cowan, R. Dionne, B.S. Galer, S. Hertz, A.R. Jadad, L.D. Kramer, D.C. Manning, S. Martin, C.G. McCormick, M.P. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, W. Robbins, J.P. Robinson, M. Rothman, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, J. Wernicke, and J. Witter Core outcome measures for chronic pain clinical trials: IMMPACT recommendations PAIN® 113 2005 9 19
11. J.E. Edwards, H.J. McQuay, and A. Moore Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain J Pain Symptom Manage 18 1999 427 437
12. M. Ethgen, I. Boutron, G. Baron, B. Giraudeau, J. Sibilia, and P. Ravaud Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease Ann Intern Med 143 2005 20 25
13. T.R. Fleming Identifying and addressing safety signals in clinical trials N Engl J Med 359 2008 1400 1402
14. A. Haidich, C. Birtsou, T. Dardavessis, I. Tirodimos, and M. Arvanitidou The quality of safety reporting in trials is still suboptimal: survey of major general medical journals J Clin Epidemiol 64 2011 124 135
15. T.A. Hammad, S.P. Pinheiro, and G.A. Neyarapally Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations Clin Trials 8 2011 559 570
16. W. Hauser, C. Bartram, E. Bartram-Wunn, and T. Tolle Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review Clin J Pain 28 2012 437 451
17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline. Structure and content of clinical study reports E3. < http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E3/E3-Guideline.pdf >; 1995 [accessed 19.10.12].
18. J.P.A. Ioannidis Adverse events in randomized trials: neglected, restricted, distorted, and silenced Arch Intern Med 169 2009 1737 1739
19. J.P.A. Ioannidis, and D.G. Contopoulos-Ioannidis Reporting of safety data from randomized trials Lancet 352 1998 1752 1753
20. J.P.A. Ioannidis, S.J. Evans, P.C. Gotzsche, R.T. O'Neill, D.G. Altman, K. Schulz, and D. Moher Better reporting of harms in randomized trials: an extension of the CONSORT statement Ann Intern Med 141 2004 781 788
21. J.P.A. Ioannidis, and J. Lau Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas JAMA 285 2001 437 443
22. J.P.A. Ioannidis, and J. Lau Improving safety reporting from randomised trials Drug Saf 25 2002 77 84
23. J.P.A. Ioannidis, C.D. Mulrow, and S.N. Goodman Adverse effects: the more you search, the more you find Ann Intern Med 144 2006 298 300
24. A.P. Jonville-Bera, B. Giraudeau, and E. Autret-Leca Reporting of drug tolerance in randomized clinical trials: when data conflict with authors' conclusions Ann Intern Med 144 2006 306 307
25. N.P. Katz The measurement of symptoms and side effects in clinical trials of chronic pain Contemp Clin Trials 33 2012 903 911
26. A.S. Kesselheim, C.T. Robertson, J.A. Myers, S.L. Rose, V. Gillet, K.M. Ross, R.J. Glynn, S. Joffe, and J. Avorn A randomized study of how physicians interpret research funding disclosures N Engl J Med 367 2012 1119 1127
27. Y.K. Loke Lack of clarity in reports of adverse events: is there any harm? PAIN® 154 2013 183 184
28. L.D. Lynd, and B.J. O'Brien Advances in risk-benefit evaluation using probabilistic simulation methods: an application of the prophylaxis of deep vein thrombosis J Clin Epidemiol 57 2004 795 803
29. I. Pitrou, I. Boutron, N. Ahmad, and P. Ravaud Reporting of safety results in published reports of randomized controlled trials Arch Intern Med 169 2009 1756 1761
30. W. Rief, J. Avorn, and A.J. Barsky Medication-attributed adverse effects in placebo groups Arch Intern Med 166 2006 155 160
31. W. Rief, A.J. Barsky, J.A. Glombiewski, Y. Nestoriuc, H. Glaesmer, and E. Braehler Assessing general side effects in clinical trials: reference data from the general population Pharmacoepidemiol Drug Saf 20 2011 405 415
32. Rief W, Globmiewski JA, Barsky AJ. Generic assessment of side effects, < http://www.GASE-scale.com >; 2009 [accessed 26.02.13].
33. W. Rief, Y. Nestoriuc, A. von Lilienfeld-Toal, I. Dogan, F. Schreiber, S.G. Hofmann, A.J. Barsky, and J. Avorn Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis Drug Saf 32 2009 1041 1056
34. D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, and W.S. Richardson Evidence based medicine: what it is and what it isn't BMJ 312 1996 71 72
35. D.L. Schriger, A.C. Chehrazi, R.M. Merchant, and D.G. Altman Use of the internet by print medical journals in 2003-2009: a longitudinal observational study Ann Emerg Med 57 2011 e3
36. J.B. Schroll, E. Maund, and P.C. Gotzsche Challenges in coding adverse events in clinical trials: a systematic review PLoS One 7 2012 e41174
37. F.D. Sheftell, M. Feleppa, S.J. Tepper, A.M. Rapoport, L. Ciannella, and M.E. Bigal Assessment of adverse events associated with triptans - methods of assessment influence the results Headache 44 2004 978 982
38. A.A. Shukralla, C. Tudur-Smith, G.A. Powell, P.R. Williamson, and A.G. Marson Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms Epilepsy Res 97 2011 20 29
39. S.M. Smith, R.D. Chang, A. Pereira, N. Shah, I. Gilron, N.P. Katz, A.H. Lin, M.P. McDermott, B.A. Rappaport, M.C. Rowbotham, C. Sampaio, D.C. Turk, and R.H. Dworkin Adherence to CONSORT harms reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review PAIN® 153 2012 2415 2421
40. J.A. Sterne, and G.D. Smith Sifting the evidence - what's wrong with significance tests? BMJ 27 2001 226 231
41. M.A. Testa, R.B. Anderson, J.F. Nackley, and N.K. Hollenberg Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril N Engl J Med 328 1993 907 913
42. R. Tsang, L. Colley, and L.D. Lynd Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials J Clin Epidemiol 62 2009 609 616
43. D.C. Turk, R.H. Dworkin, R.R. Allen, N. Bellamy, N. Brandenburg, D.B. Carr, C. Cleeland, R. Dionne, J.T. Farrar, B.S. Galer, D.J. Hewitt, A. Jadad, N.P. Katz, L.D. Kramer, D.C. Manning, C.G. McCormic, M. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, J.P. Robinson, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, and J. Witter Core outcome domains for chronic pain clinical trials: IMMPACT recommendations PAIN® 106 2003 337 345
44. L.A. Turner, K. Singh, C. Garritty, A. Tsertsvadze, E. Manheimer, L.S. Wieland, J. Galipeau, and D. Moher An evaluation of the completeness of safety reporting in reports of complementary and alternative medicine trials BMC Complement Altern Med 11 2011 67
45. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry and investigators safety reporting requirements for INDs and BA/BE studies, draft guidance. < http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351.pdf >; 2010 [accessed 23.07.12].
46. S.N. Weingart, T.K. Gandhi, A.C. Seger, D.L. Seger, J. Borus, E. Burdick, L.L. Leape, and D.W. Bates Patient-reported medication symptoms in primary care Arch Intern Med 165 2005 234 240